PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemiaZhaohui Gu, Williams E. Evans, Michelle L. Churchman et al.|Nature Genetics|2019Cited by 616
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II StudyNaval Daver, Hagop M. Kantarjian, Guillermo Garcia‐Manero et al.|Cancer Discovery|2018Cited by 570
Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantationSergio Giralt, Richard E. Champlin, Peter F. Thall et al.|Blood|2001Cited by 570
Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantationSergio Giralt, Richard E. Champlin, Peter F. Thall et al.|Blood|2001Cited by 516
Ph-like acute lymphoblastic leukemia: a high-risk subtype in adultsNitin Jain, Marina Konopleva, Ken Chen et al.|Blood|2016Cited by 385